Sildenafil benefit small in patients with idiopathic pulmonary fibrosis

Sep 22, 2010

Sildenafil failed to significantly increase exercise capacity, but did improve arterial oxygenation, shortness of breath and quality of life in patients with advanced idiopathic pulmonary fibrosis (IPF), in the first randomized trial of the medication for IPF. The study is published in the August 12, 2010, issue of the New England Journal of Medicine.

Sildenafil failed to significantly increase , but did improve arterial oxygenation, shortness of breath and quality of life in patients with advanced idiopathic pulmonary fibrosis (IPF), in the first of the medication for IPF. The study is published in the August 12, 2010, issue of the .

“While the study did not meet the primary end point of improved distance in the six-minute walk, the secondary findings on improved quality of life and better oxygenation are encouraging,” said pulmonologist Marvin Schwarz, MD, of National Jewish Health and University of Colorado, and one of the authors of the paper. “It is quite clear that these outcomes require more study.”

IPF is a progressive and fatal scarring of the lungs for which there is no approved treatment. Sildenafil is manufactured by Pfizer under the brand names Viagra and Revatio. Researchers thought sildenafil might help IPF patients by increasing blood flow to the lungs and thus improving gas exchange.

Researchers from 14 IPF centers randomized 180 IPF patients to receive oral sildenafil, 20 mg, three times daily, or placebo for 12 weeks. All patients received sildenafil in a second 12-week period.

The difference in the primary outcome was not significant, with 10 percent of patients in the sildenafil group and seven percent in the placebo group improving 20 percent or more in the distance they covered in a six-minute walk.

However, gas exchange, including arterial and carbon monoxide diffusion capacity did showed small but significant improvements. Patients also scored higher on three tests measuring quality of life and shortness of breath.

“There are no current therapies that improve survival in IPF patients, but clearly quality of life and degree of dyspnea are important,” said Dr. Schwarz.

Explore further: UN releases $1.5mn to help DR Congo fight Ebola

Provided by National Jewish Health

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Hope for patients with mild idiopathic pulmonary fibrosis

May 18, 2010

A new therapy shows promise for patients with mild idiopathic pulmonary fibrosis. According to researchers in Japan, inhaled N-acetylcysteine (NAC) monotherapy preserves more lung function in some idiopathic pulmonary fibrosis ...

New prognostic indicator for patients with IPF

Feb 20, 2009

There may be a new way to predict mortality in patients with idiopathic pulmonary fibrosis (IPF), a devastating disease that slowly petrifies the lungs. Most patients live only three years after diagnosis on average; however, ...

Rare lung disease cells indicate higher death risk

Jan 16, 2008

Large numbers of certain cells in the lungs of patients diagnosed with idiopathic pulmonary fibrosis may increase their chance of death, University of Cincinnati (UC) researchers have discovered.

Recommended for you

UN releases $1.5mn to help DR Congo fight Ebola

1 hour ago

The United Nations on Wednesday allocated $1.5 million (1.1 million euros) to help the Democratic Republic of Congo fight Ebola, just days after the country confirmed its first cases this year.

'Junk' blood tests may offer life-saving information

3 hours ago

Some 30 percent of all positive hospital blood culture samples are discarded every day because they're "contaminated"—they reflect the presence of skin germs instead of specific disease-causing bacteria.

Drug represents first potential treatment for common anemia

4 hours ago

An experimental drug designed to help regulate the blood's iron supply shows promise as a viable first treatment for anemia of inflammation, according to results from the first human study of the treatment published online today in Blood, the Journal of the American Society o ...

User comments : 0